Skip to Content

Screen width:

Latest News

News Archived

Jan
13
2015

Archer™ products now available at ArcherDX

Archer™ products use Anchored Multiplex PCR (AMP™) to generate target-enriched libraries for next-generation sequencing to detect gene rearrangements, such as fusions, insertions/deletions (indels), copy number variations (CNVs) and single-nucleotide polymorphisms (SNPs). And with the acquisition of the Enzymatics Enzyme Solutions business by Qiagen, ArcherDX was formed to continue to provide FusionPlex™ assays and a continually increasing catalog  Continue Reading »

Jan
11
2015

QIAGEN acquires Enzymatics enzyme solutions unit, a leading enabler of NGS applications

QIAGEN acquires Enzymatics enzyme solutions unit, a leading enabler of NGS applications Enzymatics products used in 80% of all global NGS sequencing reactions Strengthens QIAGEN’s universal NGS product offering and strategy to offer complete NGS workflows from sample to insight Adds comprehensive R&D, manufacturing, formulation and analytical capabilities in enzymology Strategic partnership formed with ArcherDX,  Continue Reading »

Jan
11
2015

A Customer Letter from Enzymatics’ Co-Founder

Dear Valued Customer, Since our founding in 2006, Enzymatics has been passionately committed to supporting your efforts to create groundbreaking genomic technologies with the best molecular biology enzymes, assays, and kits. We continually implement strategies to improve our business, and I am pleased to inform you that Enzymatics’ Enzyme Solutions business has merged with QIAGEN,  Continue Reading »

Nov
17
2014

The Value of Richer NGS Data Sets Using Anchored Multiplex PCR – Webinar by Brian Kudlow, PhD

December 10th, 2014 9:30 AM MST Enzymatics hosted a webinar by Brian Kudlow, PhD, Group Lead and Senior R&D Scientist at Enzymatics. Anchored Multiplex PCR (AMP™) is a novel technology to prepare target-enriched libraries from both RNA and DNA inputs for gene rearrangement detection and characterization by next-generation sequencing (NGS). AMP™ enriches for target fragments  Continue Reading »

Oct
07
2014

Archer Analysis Pipeline update, version 3.0

The Archer Analysis Pipeline has been updated from version 2.1 to 3.0 to bring greater functionality, faster analysis and more comprehensive reporting. The Archer Analysis Pipeline 3.0 is now available for download. New features include fusion visualization, variant effect prediction, known fusion database and faster analysis time.The Archer Analysis Pipeline has been updated to version  Continue Reading »

Sep
16
2014

Enzymatics to present at the Canada NGS Symposium

Archer™ by Enzymatics is headed to the Canada NGS Symposium! The symposium will bring together leading NGS specialists to discuss ideas, applications, instrumentation, methods, and best practices in NGS.  Archer™ by Enzymatics is showcasing its best-in-class fusion detection technology Anchored Multiplex PCR and  Enzymatics’ Brady Culver, Senior Scientist, will speak on “Sequencing applications of Anchored Multiplex PCR in  Continue Reading »

Aug
19
2014

NGS-based sarcoma fusion detection: Breakthroughs in clinical research – Webinar by Dr. Alex Lazar

Enzymatics, Inc. is hosting a webinar by distinguished sarcoma pathologist Alex Lazar, MD, PhD, Director of Sarcoma & Melanoma Molecular Diagnostics at the MD Anderson Cancer Center. Continue Reading »

Jun
13
2014

Archer Analysis Pipeline updates, Version 2.1

The Archer Analysis Pipeline Version 2.1 has the following new features and bug fixes: New Functionality Improved detection of complex gene fusions After mapping of the reads with Burrow Wheeler Alignment (BWA), we have improved the sensitivity of fusion detection by using BLAST and MUSCLE to find the correct mapping of the consensus to the  Continue Reading »

May
09
2014

Webinar by Dr. Anthony John Iafrate, hosted by Enzymatics, Inc.

May 20, 2014 9:00 AM MDT — Enzymatics, Inc. is hosting a webinar by renowned cancer pathologist Dr. Iafrate, Associate Professor in Pathology at Harvard Medical School. His presentation, Clinically Actionable Gene Fusions Detected with NGS, will focus on recent developments in his laboratory enabling multiplex detection of gene fusions by next-generation sequencing. A peek at the future of personalized medicine, this novel detection methodology permits stratification of patients into actionable trial groups based on the nature of the mutations and gene fusions unique to that patient. Continue Reading »

Apr
04
2014

Thon de Boer’s webinar on Archer’s Analysis Software

We’ve appreciated your feedback on the Archer Analysis Pipeline and are pleased to show you the fruits of your requests as Dr. Thon deBoer presents this webinar on New Archer Pipeline Features and Updates.

You’ll get a sneak peak at some of the new capabilities and enhancements, like the ability to probe DNA/RNA mutations and enumerate copy number variations, graphical metrics output, and better progress indications.

 Continue Reading »

Back to top